InspireMD, Inc. (NSPR)

Market Cap	44.80M
Revenue (ttm)	6.21M
Net Income (ttm)	-19.92M
Shares Out	23.46M
EPS (ttm)	-0.82
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	21,329
Open	2.140
Previous Close	2.100
Day's Range	1.870 - 2.140
52-Week Range	1.000 - 3.850
Beta	0.89
Analysts	Strong Buy
Price Target	4.63 (+142.41%)
Earnings Date	May 7, 2024

About NSPR

InspireMD, Inc., a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem le...

• Industry: Medical Devices
• Sector: Healthcare
• CEO: Marvin L. Slosman
• Employees: 65
• Stock Exchange: NASDAQ
• Ticker Symbol: NSPR

Financial Performance

In 2023, InspireMD's revenue was $6.21 million, an increase of 20.00% compared to the previous year's $5.17 million. Losses were -$19.92 million, 7.71% more than in 2022.

Analyst Forecast

According to 2 analysts, the average rating for NSPR stock is "Strong Buy." The 12-month stock price forecast is $4.63, which is an increase of 142.41% from the latest price.

Price Target

$4.63

(142.41% upside)

Analyst Consensus: Strong Buy